Digital Health Partnership Aims to Improve Treatment Experience for Patients with Rare Diseases

Rare Daily Staff

CSL Behring announced a global digital health partnership with Internet-of-Things platform service provider BrightInsight to digitally-improve treatment experiences and regulate digital health offerings in support of CSL Behring therapies.

BrightInsight provides a regulated Internet of Things platform for biopharma and medtech on Google Cloud that is built under a quality management system to support and optimize regulated drugs, devices and software through integrated data and actionable insights.

CSL Behring will use BrightInsight’s platform to develop and host digital health devices, apps, algorithms, and Software as a Medical Device (SaMD) at scale while maintaining compliance with privacy, security and regulatory requirements across the globe.

“This latest global partnership with a biopharmaceutical leader represents an important next step in achieving our mission to transform patient outcomes globally through the power of digital technology,” said Kal Patel, co-founder and CEO of BrightInsight.

CSL Behring therapeutic solutions aim to improve the lives of patients by enabling them to manage their condition with independence, confidence, and control. The partnership extends across all therapeutic areas, including immunology, hematology and respiratory, among others.

“BrightInsight’s Platform allows us to focus on therapeutic innovation, rather than the underlying digital technology,” said Brian Johnson, director, Digital Health, CSL Behring.

CSL Behring develops therapies to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

Photo: Kal Patel, co-founder and CEO of BrightInsight